The dynamic evolution of IL-8 during ICI treatment in NSCLC patients has been reported with greater benefit among patients with early decreases of IL-8 levels [78], while increased tumor necrosis factor or interferon-gamma during ICI treatment correlated with improved response and longer OS [79,80]. This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.